{
    "root": "17c593e5-6a94-458b-8a14-de3f0a51632b",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "CUVRIOR",
    "value": "20250304",
    "ingredients": [
        {
            "name": "TRIENTINE TETRAHYDROCHLORIDE",
            "code": "7360URE56Q"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "GLYCERYL DIBEHENATE",
            "code": "R8WTH25YS2",
            "drugbank_id": "https://go.drugbank.com/drugs/DB13038"
        }
    ],
    "indications": {
        "text": "cuvrior indicated treatment adult patients stable wilson 's disease de-coppered tolerant penicillamine .",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "recommended starting total daily cuvrior adults 300 mg 3,000 mg orally divided doses ( 2 times daily ) . full prescribing information recommended conversion table switching penicillamine cuvrior . ( 2.1 ) total daily cuvrior exceed 3,000 mg. ( 2.1 ) number cuvrior tablets prescribed per day equally divided among doses , divide total daily higher number tablets taken first daily dose . ( 2.1 ) take cuvrior empty stomach . ( 2.2 ) swallow tablets without crushing , chewing , dissolving tablets . ( 2.2 ) switching trientine products cuvrior substitutable milligram-per-milligram basis trientine products . ( 2.3 ) full prescribing information additional information switching trientine products . ( 2.3 ) monitoring laboratory monitoring copper adjust cuvrior according assessment laboratory monitoring copper . ( 2.4 ) full prescribing information monitoring recommendations . ( 2.4 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "cuvrior tablets , 300 mg trientine tetrahydrochloride , oblong , yellow coated , functionally scored , imprinted ol75 side . large carton ( ndc 81802-001-72 ) contains nine child-resistant small cartons ( ndc 81802-001-08 ) , containing blister pack 8 tablets ( total 72 tablets large carton ) . fewest number tablets dispensed 8 tablets small carton . remove tablets blister pack time dosing .",
    "adverseReactions": "cuvrior contraindicated patients hypersensitivity trientine excipients cuvrior [ ( 5.4 ) ] .",
    "indications_original": "CUVRIOR is indicated for the treatment of adult patients with stable Wilson's disease who are de-coppered and tolerant to penicillamine.",
    "contraindications_original": "Recommended Dosage and Administration Starting total daily dosage of CUVRIOR in adults is 300 mg up to 3,000 mg orally in divided doses (2 times daily). See full prescribing information for recommended conversion table when switching from penicillamine to CUVRIOR. ( 2.1 ) Total daily dosage of CUVRIOR should not exceed 3,000 mg. ( 2.1 ) If the number of CUVRIOR tablets prescribed per day cannot be equally divided among doses, then divide total daily dosage such that the higher number of tablets is taken with the first daily dose. ( 2.1 ) Take CUVRIOR on an empty stomach. ( 2.2 ) Swallow tablets without crushing, chewing, or dissolving tablets. ( 2.2 ) Switching from Other Trientine Products CUVRIOR is not substitutable on a milligram-per-milligram basis with other trientine products. ( 2.3 ) See full prescribing information for additional information on switching from other trientine products. ( 2.3 ) Clinical Monitoring and Laboratory Monitoring of Copper Adjust CUVRIOR dosage according to clinical assessment and laboratory monitoring of copper. ( 2.4 ) See full prescribing information for monitoring recommendations. ( 2.4 )",
    "warningsAndPrecautions_original": "CUVRIOR tablets, 300 mg of trientine tetrahydrochloride, are oblong, yellow coated, functionally scored, and imprinted with OL75 on each side. Each large carton (NDC 81802-001-72) contains nine child-resistant small cartons (NDC 81802-001-08), each containing a blister pack of 8 tablets (a total of 72 tablets in the large carton). The fewest number of tablets that can be dispensed is 8 tablets in a small carton.\n                  Do not remove tablets from the blister pack until the time of dosing.",
    "adverseReactions_original": "CUVRIOR is contraindicated in patients with hypersensitivity to trientine or to any of the excipients in CUVRIOR [see Warnings and Precautions (5.4)].",
    "drug": [
        {
            "name": "CUVRIOR"
        }
    ]
}